BOTHELL, Wash., April 17 /PRNewswire-FirstCall/ -- Cardiac Science Corporation , a global leader in advanced cardiac monitoring and defibrillation products, and holder of over 100 patents relating to proprietary technology, devices and disposables, announced today that it secured three new U.S. patents recently.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO )
The first patent covers an external defibrillation module for integration into standard hospital patient monitors. The module has numerous modes of operation, including fully-automatic, and is designed for integration with generic patient monitoring equipment to share certain functions and provide patients with the appropriate anti-tachycardia therapy when needed. It was issued on February 28, 2006, is Patent No. 7,006,865, and is titled “Automatic Defibrillation Module for Integration with Standard Patient Monitoring Equipment.”
The second patent covers a publicly-available portable defibrillator capable of being used by a bystander to automatically deliver life-saving defibrillation shock(s) to a heart attack victim. The patent was issued on January 31, 2006, and is Patent No. 6,993,386 and is titled “Public Access Defibrillation.” It is a continuation, in part, of Cardiac Science’s U.S. patent No. 6,658,290.
The third patent is a unique method of microvolt T-wave Alternans testing. It covers a non-invasive testing method that employs a statistical analysis to identify microvolt abnormalities in a patient’s electrocardiogram in order to determine a patient’s vulnerability to sudden cardiac arrest (SCA). This patent was issued on January 3, 2006, and is Patent No. 6,983,183, and is titled “Method and Apparatus for Monitoring Cardiac Patients for T-Wave Alternans.”
“These new patents expand the entire body of intellectual property surrounding the Company’s devices and technology,” said John Hinson, president and chief executive officer of Cardiac Science. “The first incorporates our defibrillation technology into standard patient monitoring systems, the second extends our existing defibrillation capabilities, and the third adds to our domain knowledge in evaluating the risk of cardiovascular death.”
About Cardiac Science Corporation
Cardiac Science Corporation develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor- defibrillators and cardiology data management systems. Cardiac Science Corporation also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services.
The company is the successor to various entities that have owned and operated cardiology-related businesses, which sold products under the trusted brand names Burdick(R), Powerheart(R), and Quinton(R). Cardiac Science Corporation is headquartered in Bothell, WA, and also has operations in Lake Forest, California, Deerfield, Wisconsin, Shanghai, China, Copenhagen, Denmark and Manchester, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements. The words “believe,” “expect,” “intend,” anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that we will be able to successfully commercialize applications incorporating recently patented technology. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the registration statement on Form S-4/A that was filed by Cardiac Science Corporation under the name CSQ Holding Company on July 28, 2005, under the caption “Risk Factors,” and in the Annual Reports of Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. on Form 10-K for the year ended December 31, 2004, under the captions “Certain Factors that May Affect Future Results,” in Cardiac Science Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 under the caption “Certain Factors that May Affect Future Results” and in other documents, we file with the Securities and Exchange Commission. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
Contact: Mike Matysik Cardiac Science Corp. Sr. Vice President and CFO 425-402-2009
Photo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comCardiac Science Corp.
CONTACT: Mike Matysik, Sr. Vice President and CFO of Cardiac ScienceCorp., +1-425-402-2009
Web site: http://www.cardiacscience.com/
